Fingerprint Fingerprint is based on mining the text of the persons scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 2 Similar Profiles
Pharmacokinetics Medicine & Life Sciences
Verapamil Medicine & Life Sciences
Antipyrine Medicine & Life Sciences
Half-Life Medicine & Life Sciences
Obesity Medicine & Life Sciences
Benzodiazepines Medicine & Life Sciences
Diazepam Medicine & Life Sciences
Acetaminophen Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1972 2017

Improving the tools of clinical pharmacology: Goals for 2017 and beyond

Zineh, I., Abernethy, D., Hop, C. E. C. A., Bello, A., McClellan, M. B., Daniel, G. W. & Romine, M. H. Jan 1 2017 In : Clinical Pharmacology and Therapeutics. 101, 1, p. 22-24 3 p.

Research output: Contribution to journalArticle

Drug Evaluation
Clinical Pharmacology
Delivery of Health Care

Use of biomedical ontologies for integration of biological knowledge for learning and prediction of adverse drug reactions

Zaman, S., Sarntivijai, S. & Abernethy, D. R. Mar 15 2017 In : Gene Regulation and Systems Biology. 11, 1177625017696075

Research output: Contribution to journalArticle

Biological Ontologies
Drug-Related Side Effects and Adverse Reactions

GPS for QSP: A summary of the ACoP6 symposium on quantitative systems pharmacology and a stage for near-term efforts in the field

Musante, C. J., Abernethy, D. R., Allerheiligen, S. R., Lauffenburger, D. A. & Zager, M. G. Sep 1 2016 In : CPT: Pharmacometrics and Systems Pharmacology. 5, 9, p. 449-451 3 p.

Research output: Contribution to journalReview article

Systems Biology
Drug Discovery
Molecular Biology

In Memoriam: David A Flockhart, 1952-2015

Greenblatt, D. J. & Abernethy, D. R. 2016 In : Clinical Pharmacology in Drug Development.

Research output: Contribution to journalArticle

Linking MedDRA®-Coded Clinical Phenotypes to Biological Mechanisms by the Ontology of Adverse Events: A Pilot Study on Tyrosine Kinase Inhibitors

Sarntivijai, S., Zhang, S., Jagannathan, D. G., Zaman, S., Burkhart, K. K., Omenn, G. S., He, Y., Athey, B. D. & Abernethy, D. R. Mar 22 2016 In : Drug Safety. p. 1-11 11 p.

Research output: Contribution to journalArticle

Biological Ontologies
Protein-Tyrosine Kinases
Monoclonal Antibodies
United States Food and Drug Administration